CAMPs Evidence Compendium 2025: Unifying Cellular, Acellular, and Matrix Products for Chronic Wound Care
Summary: This October 2025 compendium from the Journal of Wound Care consolidates evidence on Cellular, Acellular, and Matrix-like Products (CAMPs), including placental allografts and ECM scaffolds, for chronic wounds like DFUs, VLUs, and pressure ulcers. Featuring 40+ authors, it reviews RCTs, case series, and economic models showing 50-98% closure rates, 35-80% amputation reductions, and $170/pt savings, while addressing reimbursement caps and fraud. It advocates MDT integration, fixed-fee models ($400-704/cm²), and registries for standardized coverage, positioning CAMPs as early interventions to enhance granulation and prevent complications.
Key Highlights:
- Authors: 50+ experts, including William Tettelbach, Martha Kelso, David Armstrong; editorial team led by Shruti Kamath.
- Evidence: dACM RCT (50% closure vs 35% SOC); FT-DPM (48% vs 27%); carePATCH (77.4-100% PAR); overall 86% closure in series.
- Reimbursement: Proposes $400/cm² fixed fee for $2B savings; LCD limits (8 apps/16 wks) cause 30% failure; calls for AI oversight.
- Policy: National Coverage Determination for equity; registries for accountability; targets fraud without access barriers.
- Outcomes: QALY gains, fewer admissions; mechanisms: granulation promotion, infection control, ECM support.
Keywords: CAMPs, placental allografts, chronic wounds, reimbursement policy, wound care evidence